Tarsus Pharmaceuticals Business Summary

Tarsus Pharmaceuticals, Inc. (TARS) is a commercial-stage biopharmaceutical company that generates revenue primarily through the net product sales of XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment for Demodex blepharitis. The company’s business model is centered on the commercialization of first-in-class therapeutics for high-unmet-need conditions, with primary segments in eye care, dermatology, and infectious disease prevention. Revenue is further bolstered by international licensing and royalty agreements, notably with Grand Pharmaceuticals for the Greater China market. Tarsus maintains a dominant market position as a category leader in the anterior segment, competing directly with ophthalmic developers such as Azura Ophthalmics, Ocular Therapeutix, and ONL Therapeutics by targeting the biological root causes of parasitic and inflammatory ocular diseases. Tarsus was co-founded in 2016 by CEO and Chairman Bobak Azamian, MD, PhD, and Michael Ackermann, PhD, both of whom possess extensive venture and operational backgrounds from firms like Versant Ventures, Third Rock Ventures, and Allergan. The leadership team is anchored by CFO and Chief Strategy Officer Jeff Farrow, who previously held senior roles at Global Blood Therapeutics and ZS Pharma, and COO Sesha Neervannan, PhD, a former SVP of Global Pharmaceutical Development at Allergan. Clinical operations are directed by Chief Medical Officer Elizabeth Yeu, MD, a renowned anterior segment specialist and former President of the ASCRS. The company’s growth is supported by a high-profile board including Bhaskar Chaudhuri of Frazier Healthcare Partners and Andrew Goldberg of Marshall Wace, with significant institutional backing from Jennison Associates, Geode Capital Management, and Vanguard Group.